Scholarlink

Aims <p>This study aimed to evaluate the clinical outcomes of switching from disposable insulin delivery pens to reusable insulin pens with a penfill cartridge system for the co-formulation of insulin degludec and insulin aspart (IDegAsp) in patients with type 2 diabetes (T2D) in Türkiye. We assessed the impact on glycemic control to evaluate the sustainability of this transition.</p> Methods <p>A total of 226 adults with T2D who were initiating or switching to IDegAsp reusable cartridge insulin pens at a tertiary center in Türkiye were followed for 6&#xa0;months. Data were retrospectively extracted from the medical records at baseline (prior to switching) and at follow-up visits after 3 and 6&#xa0;months of IDegAsp Penfill reusable cartridges.</p> Results <p>Initiating the IDegAsp reusable cartridge insulin pen in patients who previously used basal-bolus, basal, or premixed insulin therapies with disposable insulin pens was associated with a significant reduction in mean glycated hemoglobin (HbA1c) [mean change -1.0% (95% confidence interval (CI) − 2.2 to − 0.20; p &lt; 0.001)], [− 1.4% (95% CI − 2.3 to − 0.4; p &lt; 0.001)], and [− 0.9% (CI − 1.7 to − 0.1; p &lt; 0.001)]. Switching from IDegAsp disposable insulin pens to the reusable system demonstrated noninferior outcomes [− 0.08% (CI − 0.2 to 0.1; p = 0.629)]. The mean total daily insulin dose and body weight were also significantly lower in patients who were switched from basal-bolus insulin, basal insulin or premixed insulin therapies (p &lt; 0.001 and p &lt; 0.001, respectively).</p> Conclusion <p>Initiating or switching to the IDegAsp reusable pen with the insulin cartridge system in a real-world population of people with T2D in Türkiye was associated with improved or maintained glycemic control.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Switching to insulin degludec/aspart penfill reusable cartridges in patients with type 2 diabetes mellitus: real-life outcomes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月19日

查看全文
  • Sezin Dogan Çakır,
  • Hatice Deniz Yücel,
  • Zeynep Akgül Kızılçay,
  • Mine Adaş

摘要

Aims

This study aimed to evaluate the clinical outcomes of switching from disposable insulin delivery pens to reusable insulin pens with a penfill cartridge system for the co-formulation of insulin degludec and insulin aspart (IDegAsp) in patients with type 2 diabetes (T2D) in Türkiye. We assessed the impact on glycemic control to evaluate the sustainability of this transition.

Methods

A total of 226 adults with T2D who were initiating or switching to IDegAsp reusable cartridge insulin pens at a tertiary center in Türkiye were followed for 6 months. Data were retrospectively extracted from the medical records at baseline (prior to switching) and at follow-up visits after 3 and 6 months of IDegAsp Penfill reusable cartridges.

Results

Initiating the IDegAsp reusable cartridge insulin pen in patients who previously used basal-bolus, basal, or premixed insulin therapies with disposable insulin pens was associated with a significant reduction in mean glycated hemoglobin (HbA1c) [mean change -1.0% (95% confidence interval (CI) − 2.2 to − 0.20; p < 0.001)], [− 1.4% (95% CI − 2.3 to − 0.4; p < 0.001)], and [− 0.9% (CI − 1.7 to − 0.1; p < 0.001)]. Switching from IDegAsp disposable insulin pens to the reusable system demonstrated noninferior outcomes [− 0.08% (CI − 0.2 to 0.1; p = 0.629)]. The mean total daily insulin dose and body weight were also significantly lower in patients who were switched from basal-bolus insulin, basal insulin or premixed insulin therapies (p < 0.001 and p < 0.001, respectively).

Conclusion

Initiating or switching to the IDegAsp reusable pen with the insulin cartridge system in a real-world population of people with T2D in Türkiye was associated with improved or maintained glycemic control.